Citations Appearing in 2001

  1. Acosta, E.P. and H.H. Balfour. Acyclovir for treatment of postherpetic neuralgia: Efficacy and pharmacokinetics. Antimicrobial Agents and Chemotherapy 45(10):2771- 2774, 2001.
  2. Balasubramanian, P., M. Chandy, R. Krishnamoorthy and A. Srivastava. Evaluation of existing limited sampling models for busulfan kinetics in children with beta thalassaemia major undergoing bone marrow transplantation. Bone Marrow Transplantation 28(9):821-825, 2001.
  3. Bissett, D., H.L. McLeod and B. Sheedy. Phase I dose-escalation and pharmacokinetic study of a novel folate analogue. British Journal of Cancer 84(3):308-312, 2001.
  4. Bleyzac, N., G. Souillet, P. Magron, A. Janoly, P. Martin, Y. Bertrand, C. Galambrun, Q. Dai, P. Maire, R.W. Jellife and G. Aulagner. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplantation 28(8):743-751, 2001.
  5. Bleyzac, N., V. Varnier, J.M. Labaune, S. Corvaisier, P. Maire, R.W. Jelliffe, G. Putet and G. Aulagner. Population pharmacokinetics of amikacin at birth and interindividual variability in renal maturation. European Journal of Clinical Pharmacology 57(6- 7):499-504, 2001.
  6. Bondareva, I.B., A.V. Sokolov, I.F. Tischenkova and R.W. Jelliffe. Population pharmacokinetic modelling of carbamazepine by using the iterative Bayesian (IT2B) and the nonparametric EM (NPEM) algorithms: implications for dosage. Journal of Clinical Pharmacy and Therapeutics 26(3):213-223, 2001.
  7. Brix, G., S.I. Ziegler, M.E. Bellemann, J. Doll, R. Schosser, R. Lucht, H. Krieter, D. Nosske and U. Haberkorn. Quantification of [F-18] FDG uptake in the normal liver using dynamic PET: Impact and modeling of the dual hepatic blood supply. Journal of Nuclear Medicine 42(8):1265-1273, 2001.
  8. Burstein, A.H., E. Reed and A.C. Tompkins. Phenylacetate pharmacokinetics based on iterative two-stage population analysis. Pharmacotherapy 21(3):281-286, 2001.
  9. Cameron, D.A., A.A. Ritchie and W.R. Miller. The relative importance of proliferation and cell death in breast cancer growth and response to tamoxifen. European Journal of Cancer 37(12):1545-1553, 2001.
  10. Clive, S., D.J. Webb, A. MacLellan, A. Young, B. Byrne, L. Robson, J.F. Smyth and D.I. Jodrell. Forearm blood flow and local responses to peptide vasodilators: A novel pharmacodynamic measure in the phase I trial of antagonist G, a neuropeptide growth factor antagonist. Clinical Cancer Research 7(10):3071-3078, 2001.
  11. Drusano, G.L., J.A. Bilello, S.L. Preston, E. O’Mara, S. Kaul, S. Schnittman and R. Echols. Hollow-fiber unit evaluation of a new human immunodeficiency virus type 1 protease inhibitor, BMS-232632, for determination of the linked pharmacodynamic variable. Journal of Infectious Diseases 183(7):1126-1129, 2001.
  12. Drusano, G.L., S.L. Preston and C. Hardalo. Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint. Antimicrobial Agents and Chemotherapy 45(1):13-22, 2001.
  13. Dutta, S., E. Samara,W. Lam, G.R. Granneman, P.T. Leese and R.J. Padley. Multipledose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Clinical Drug Investigation 21(2):129-136, 2001.
  14. Egorin, M.J., E.G. Zuhowski, D.M. Rosen, D.L. Sentz, J.M. Covey and J.L. Eiseman. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17 demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemotherapy and Pharmacology 47(4):291-302, 2001.
  15. Fetterly, G.J., J.M.Tamburlin and R.M.Straubinger. Paclitaxel pharmacodynamics: Application of a mechanism-based neutropenia model. Biopharmaceutics and Drug Disposition 22(6):251-261, 2001.
  16. Formentini, E.A., O.N. Mestorino, O.N. Marino and J.O.O. Errecalde. Pharmacokinetics of ricobendazole in calves. Journal of Veterinary Pharmacology and Therapeutics 24(3):199-202, 2001.
  17. Gallo, J.M. Pharmacokinetics: Model structure and transport systems (Reprinted from Transport Processes in Pharmaceutical Systems, pg 55-86, 2000). Clinical Research and Regulatory Affairs 18(3):235-266, 2001.
  18. Goldstein, S.L., D.J. Murry, S. May, A. Aleksic, K.M. Sowinski and S. Blaney. Meropenem pharmacokinetics in children and adolescents receiving hemodialysis. Pediatric Nephrology 16(12):1015-1018, 2001.
  19. Grem, J.L., M. Quinn, A.S. Ismail, C.H. Takimoto, R.Lush, D.J. Liewehr, S.M Steinberg, F.M. Balis, A.P. Chen, B.P. Monahan, N. Harold,W. Corse, J.Pang, R.F Murphy, C.J. Allegra and J.M. Hamilton. Pharmacokinetics and pharmacodynamic effects of 5-fluorouracil given as a one-hour intravenous infusion. Cancer Chemotherapy and Pharmacology 47(2):117-125, 2001.
  20. Groll, A.H., B.M. Gullick and R. Petraitiene. Compartmental pharmacokinetics of the antifungal echinocandin caspofungin (MK-0991) in rabbits. Antimicrobial Agents and Chemotherapy 45(2):596-600, 2001.
  21. Groll, A.H., D. Mickiene, V. Petraitis, R. Petraitiene, K.H. Ibrahim, S.C. Piscitelli, I. Bekersky and T.J. Walsh. Compartmental pharmcokinetics and tissue distribution of the antifungal echinocandin lipopeptide micafungin (FK463) in rabbits. Antimicrobial Agents and Chemotherapy 45(12):3322-3327, 2001.
  22. Groll, A.H., D. Mickiene, R. Petraitiene, V. Petraitis, C.A. Lyman, J.S. Bacher, S.C. Piscitelli and T.J. Walsh. Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): Reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling. Antimicrobial Agents and Chemotherapy 45(10):2845-2855, 2001.
  23. Haberkorn, U., M.E. Bellemann and G. Brix. Apoptosis and changes in glucose transport early after treatment of Morris hepatoma with gemcitabine. European Journal of Nuclear Medicine 28(4):418-425, 2001.
  24. Herrington, J.D., J.A. Figueroa, M.N. Kirstein, W.C. Zamboni and C.F. Stewart. Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction. Cancer Chemotherapy and Pharmacology 47(1):89-93, 2001.
  25. Jodrell, D.I., M. Stewart, R. Aird, G. Knowles, A. Bowman, L. Wall, J. Cummings and C. McLean. 5-fluorouracil steady state pharmacokinetics and outcome in patients receiving protracted venous infusion for advanced colorectal cancer. British Journal of Cancer 84(5):600-603, 2001.
  26. Kakuda, T.N., L.M. Page, P.L. Anderson, K. Henry, T.W. Schacker, F.S. Rhame, E.P. Acosta, R.C. Brundage and C.V. Fletcher. Pharmacological basis for concentration controlled therapy with zidovudine, lamivudine, and indinavir. Antimicrobial Agents and Chemotherapy 45(1):236-242, 2001.
  27. Kozusko, F., P.H. Chen, S.G. Grant, B.W. Day and J.C. Panetta. A mathematical model of in vitro cancer cell growth and treatment with the antimitotic agent curacin A. Math Bioscience 170(1):1-16, 2001.
  28. Krance, R.A., C.A. Hurwitz, D.R. Head, S.C. Raimondi, F.G. Behm, K.R. Crews, D.K. Srivastava, H. Mahmoud, W.M. Roberts, X. Tong, R.L. Blakley and R.C. Ribeiro. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. Journal of Clinical Oncology 19(11):2804-2811, 2001.
  29. Krynetskaia, N.F., J.Y. Feng, E.Y. Krynetski, J.V. Garcia, J.C. Panetta, K.S. Anderson and W.E. Evans. Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drug. FASEB Journal 15(11):1902-1908, 2001.
  30. Krzyzanski, W. and W.J. Jusko. Indirect pharmacodynamic models for responses with multicompartmental distribution or polyexponential disposition. Journal of Pharmacokinetics and Pharmacodynamics 28(1):57-78, 2001.
  31. Kuo, G.M., D.T. Boumpas, G.G. Illei, C. Yarboro, F. Pucino and A.H. Burstein. Fludarabine pharmacokinetics after subcutaneous and intravenous administration in patients with lupus nephritis. Pharmacotherapy 21(5):528-533, 2001.
  32. Li, X.J., D. Feng and K.P. Wong. A general algorithm for optimal sampling schedule design in nuclear medicine imaging. Computer Methods and Programs in Biomedicine 65(1):45-59, 2001.
  33. Macchi-Anderson, M., B. Charpiat, R.W. Jelliffe, C. Ducerf, N. Fourcade and J. Baulieux. Failure of traditional trough levels to predict tacrolimus concentrations. Therapeutic Drug Monitoring 23(2):129-133, 2001.
  34. Magee, M.H., R.A. Blum, C.D. Lates and W.J. Jusko. Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. Journal of Clinical Pharmacology 41(11):1180-1194, 2001.
  35. Mager, D.E. and W.J. Jusko. Pharmacodynamic modeling of time-dependent transduction systems. Clinical Pharmacology and Therapeutics 70(3):210-216, 2001.
  36. Mager D.E. and W.J. Jusko. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. Journal of Pharmacokinetics and Pharmacodynamics 28(6):507-532, 2001.
  37. Marier, J.F., F. Beaudry, M.P. Ducharme, D. Fortin, J.P. Moreau, R. Masse and P. Vachon. A pharmacokinetic study of amoxycillin in febrile beagle dogs following repeated administrations of endotoxin. Journal of Veterinary Pharmacology and Therapeutics 24(6):379-383, 2001.
  38. Meno-Tetang, G.M.L., R.A. Blum, K.E. Schwartz and W.J. Jusko. Effects of oral prasterone (dehydroepiandrosterone) on single-dose pharmacokinetics of oral prednisone and cortisol suppression in normal women. Journal of Clinical Pharmacology 41(11):1195-1205, 2001.
  39. Oguri T., T. Isobe, K. Mitsuta, K.Masuda, H. Daga, N. Ishikawa, K. Fujitaka, M. Miyazaki and N.Kohno. Carboplatin AUC and gamma-glutamylcysteine synthetase gene expression in peripheral mononuclear cells of lung cancer patients. Anticancer Research 21(6A):3933-3936, 2001.
  40. Olver, I., M. Davy, D. Luftner, S.H. Park, M. Egorin, A. Ellis and L. Webster. A phase I study of paclitaxel and altretamine as second-line therapy to cisplatin regimens for ovarian cancer. Cancer Chemotherapy and Pharmacology 48(2):109-114, 2001.
  41. Papadopoulos, K.P., M.J. Egorin and M. Huang. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m(2) continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer. Cancer Chemotherapy and Pharmacology 47(1):45-50, 2001.
  42. Parker, R.S., and F.J. Doyle. Control-relevant modeling in drug delivery. Advanced Drug Delivery Reviews 48(2-3):211-228, 2001.
  43. Perlstein, I., D. Stepensky, D. Sapoznikov and A. Hoffman. Power spectral analysis of heart rate variability in rats as a quantitative tool in the PK-PD analysis of the parasympatholytic activity of atropine. Pharmaceutical Research 18(8):1220-1225, 2001.
  44. Petraitiene, R., V. Petraitis, A.H. Groll, T. Sein, S. Piscitelli, M. Candelario, A. Field- Ridley, N. Avila, J. Bacher and T.J. Walsh. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrobial Agents and Chemotherapy 45(3):857-869, 2001.
  45. Puchalski, T.A., W. Krzyzanski, R.A. Blum and W.J. Jusko. Pharmacodynamic modeling of lansoprazole using an indirect irreversible response model. Journal of Clinical Pharmacology 41(3):251-258, 2001.
  46. Ramakrishnan R. and W.J. Jusko. Interactions of aspirin and salicylic acid with prednisolone for inhibition of lymphocyte proliferation. International Immunopharmacology 1(11):2035-2042, 2001.
  47. Royce, M.E., P.M. Hoff, P. Dumas, Y. Lassere, J.J. Lee, J. Coyle, M.P. Ducharme, R. De Jager and R. Padzur. Phase I and pharmacokinetic study of exatecan mesylate (DX-8951f): A novel camptothecin analog. Journal of Clinical Oncology 19(5):1493- 1500, 2001.
  48. Samara, E., S. Dutta and G.L. Cao. Single-dose pharmacokinetics of atrasentan, an endothelin-A receptor antagonist. Journal of Clinical Pharmacology 41(4):397-403, 2001.
  49. Sharma, S., N. Kemeny, G.K. Schwartz, D. Kelsen, E. O’Reilly, D. Ilson, J. Coyle J, R.L. De Jager, M.P. Ducharme, S. Kleban, E. Hollywood and L.B. Saltz. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24- hour infusions three of every four weeks. Clinical Cancer Research 7(12):3963-3970, 2001.
  50. Sowinski, K.M., B.A. Mueller, D.W. Grabe, H.J. Manley, R.F. Frye, G.R. Bailie and M.A. Marx. Cefazolin dialytic clearance by high-efficiency and high-flux hemodialyzers. American Journal of Kidney Diseases 37(4):766-776, 2001.
  51. Stecklair, K.P. D.R. Hamburger, M.J. Egorin, R.A. Parise, J.M. Covey and J.L. Eiseman. Pharmacokinetics and tissue distribution of halofuginone (NSC 713205) in CD2F1 mice and Fischer 344 rats. Cancer Chemotherapy and Pharmacology 48(5):375- 382, 2001.
  52. Stroud, J.R., P. Muller and G.L. Rosner. Optimal sampling times in population pharmacokinetic studies. Journal of the Royal Statistical Society Series C-Applied Statistics 50:345-359, 2001.
  53. Suarez-Kurtz, G., F.M. Ribeiro, R.C.E. Estrela, F.L. Vicente and C.J. Struchiner. Limited-sampling strategy models for estimating the pharmacokinetic parameters of 4-methylaminoantipyrine, an active metabolite of dipyrone. Brazilian Journal of Medical and Biological Research 34(11):1475-1485, 2001.
  54. Tornatore, K.M., K.W. Garey, N. Saigal, K. Reed, B.Murray, E. Ingalls, R. DiFrancesco, A. Forrest, G. Morse and R. Venuto. Ganciclovir pharmacokinetics and cytokine dynamics in renal transplant recipients with cytomegalovirus infection. Clinical Transplantation 15(5):297-308, 2001.
  55. van de Poll, M.E.C., M.V. Relling, E.G. Schuetz, P.L. Harrison, W. Hughes, and P.M. Flynn. The effect of atovaquone on etoposide pharmacokinetics in children with acute lymphoblastic leukemia. Cancer Chemotherapy and Pharmacology 47(6):467- 472, 2001.
  56. van Kesteren, C., R.A.A. Mathot, L. Lopez-Lazaro, E. Cvitkovic, A. Taamma, J.M. Jimeno, C. Guzman, J.H.M. Schellens, J.L. Misset, E. Brain, M.J.X. Hillebrand, H. Rosing and J.H. Beijnen. A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion. Cancer Chemotherapy and Pharmacology 48(6):459-466, 2001.
  57. Wagner, K.R., S. Hamed, D.W. Hadley, A.L. Gropman, A.H. Burstein, D.M. Escolar, E.P. Hoffman, and K.H. Fischbeck. Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Annals of Neurology 49(6):706-711, 2001.
  58. Westervelt, P., R.A. Brown, D.R. Adkins, H. Khoury, P. Curtin, D. Hurd, S.M. Luger, M.K. Ma, T.J. Ley and J.F. DiPersio. Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood 98(2):266-271, 2001.
  59. Williams, L.E., B.G. Beatty, J.E. Shively and J.D. Beatty. Accumulation of radiolabeled anti-CEA antibody (mT84.66) in the case of multiple LS174T tumors in a nude mouse model. Cancer Biotherapy and Radiopharmaceuticals 16(2):147-157, 2001.
  60. Williams, L.E., A.M. Wu, P.J. Yazaki, A. Liu, A.A. Raubitschek, J.E. Shively and J.Y.C. Wong. Numerical selection of optimal tumor imaging agents with application to engineered antibodies. Cancer Biother Radio 16(1):25-35, 2001.
  61. Wong, H., D.W. Rurak, S. Kumar, E. Kwan, F.S. Abbott and K.W. Riggs. Dose-dependent pharmacokinetics and metabolism of valproic acid in newborn lambs and adult sheep. Drug Metabolism and Disposition 29(5):664-675, 2001.
  62. Yazaki, P.J., A.M. Wu, S.W. Tsai, L.E. Williams, D.N. Ikle, J.Y.C. Wong, J.E. Shively and A.A. Raubitschek. Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and T84.66 minibody: Comparison to radioiodinated fragments. Bioconjugate Chemistry 12(2):220-228, 2001.
  63. Yeoh, E.J.A., J.M. Cunningham G.C. Yee D. Hunt, J.A. Houston, S.L. Richardson, C.F. Stewart, P.J. Houghton, L.C. Bowman and A.J. Gajjar. Topotecan-filgrastim combination is an effective regimen for mobilizing peripheral blood stem cells. Bone Marrow Transplantation 28(6):563-571, 2001.
  64. Yu, L.X., C.D. Ellison, D.P. Conner, L.J. Lesko and A.S. Hussain. Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. AAPS Pharmsci 3(3):24, 2001.
  65. Yule, S.M., L. Price and M. Cole. Cyclophosphamide metabolism in children following a 1-h and a 24-h infusion. Cancer Chemotherapy and Pharmacology 47(3):222-228, 2001.
  66. Zamboni, W.C., D.Z. D’Argenio, C.F. Stewart, T. MacVittie, B.J. Delauter, A.M. Farese, D.M. Potter, N.M. Kubat, D. Tubergen and M.J. Egorin. Pharmacodynamic model of topotecan-induced time course of neutropenia. Clinical Cancer Research 7(8):2301-2308, 2001.
  67. Zamboni, W.C., D.I. Luftner and M.J. Egorin. The effect of increasing topotecan infusion from 30 minutes to 4 hours on the duration of exposure in cerebrospinal fluid. Annals of Oncology 12(1):119-122, 2001.